Aescap 2.0 is a biotech fund that invests in mainly European and American publicly listed medical companies. It invests in highly innovative companies that develop and market new, next generation medicines and to a lesser extent diagnostics and medical devices. Investors can enter and exit the fund twice a month. Aescap 2.0 has a focused portfolio, investing in approximately 18 companies chosen from a total universe of almost 800 listed companies in the biotech sector.
The fund is significantly out-performing its benchmark, the Nasdaq Biotech Index (NBI). It only invests in those companies with an outstanding management team, developing innovative products and having a low risk profile. But as important, a company has to be seriously undervalued before it will be taken up by the fund.
In order to reduce the risks of investing in this sector, the fund diversifies its portfolio over several disease areas, different phases of company development and over several geographical areas. Read more about our strategy here. The Fund’s objective is to make an average minimum Annual Net Return (after deduction of costs) of +20% over the mid-term (4-5 years). The minimum subscription amount is €101.000,-. For wealth managers there is no minimum investment amount, though the minimum subscription amount is EUR 10.000,- (this amount can be divided over several investors).
ISIN Code Aescap 2.0: NL0012343958
Bloomberg: AESCAPI NA Equity
Net Performance at 14-02-21:
*Inception of the fund at 28-03-2016